Endo International - Why Either A Short Or Long Position Is Too Risky For Me
The Value Investor • Wed, Jun. 25
- Endo International acquires DAVA in a deal with a potential value of $600 million.
- The deal seems fine and corresponds to the recently adjusted strategy.
- CEO De Silva appears to copy Valeant's acquisition-based strategy combined with a lean business model.
- His past ties to Valeant could make Endo a target itself, I shun the shares given the aggressive accounting and valuation.